NCT00001457View on ClinicalTrials.gov

Lamivudine for Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 1995

Study Completion Date

September 30, 2005

Conditions
Chronic Hepatitis BChronic Hepatitis DGlomerulonephritisPolyarteritis Nodosa
Interventions
DRUG

Lamivudine

Trial Locations (1)

20892

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00001457 - Lamivudine for Chronic Hepatitis B | Biotech Hunter | Biotech Hunter